Wesley Research Institute
Donate
Now

Myositis is a disorder in which the immune system attacks the muscles. It is hoped that this new treatment may help improve the symptoms of this disease.

 

Research Objectives

Status

Current

Recruitment

Open

Patient Group

Idiopathic Inflammatory Myopathy/Myositis Status: Current

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored
Sponsors: Argenx BV (global) and ICON Clinical Research Pty Ltd (Local)

Lead investigator

  • Dr Daman Langguth

Clinical trial coordinator

  • Venita Bali

Technical title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathies

About this research project

The research project is testing a new treatment for Active Idiopathic Inflammatory Myopathy. This is a disorder in which the immune system attacks the muscles. This leads to muscle weakness and may affect other organs of the body.

The potential new treatment being tested is called efgartigimod (also called ARGX113). It is hoped that efgartigimod may help improve the symptoms of myositis.

 

Latest News

Choosing the Right Format for Your Research

With so many publication types available, one of the most common questions we hear from researchers is: “How do I know which format is right for my study?” In this blog we help guide you.

Allie’s Growing Impact in Spatial Biology Research

We're celebrating the curiosity, determination and innovation of women and girls in STEM and shining a spotlight on one of the newest members of the Wesley Research Institute team, Allie, who has recently joined the Queensland Spatial Biology Centre (QSBC). 

New Study Reveals Hidden Immune Activity in Cardiac Sarcoidosis Using Spatial Biology 

A new study led by researchers at Wesley Research Institute, published in the European Heart Journal—one of the world’s most widely read cardiology journals—marks a significant advance in cardiac sarcoidosis (CS) research.
1 2 3 33
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram